Every material Form 8-K GT Biopharma, Inc. has filed with the SEC since September 15, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
GT Biopharma received notice from Nasdaq on September 22, 2026, that it has regained compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company's common stock maintained a closing bid price above $1.00 for at least ten consecutive business days, which Nasdaq required. The regained compliance removes the risk of delisting that the company had faced under the earlier deadline of November 16, 2026.
Nasdaq notified GT Biopharma on September 22, 2026 that it regained compliance with the minimum bid price requirement.
The stock had closed below $1.00 for 30 consecutive business days, leading to a Nasdaq notice on November 20, 2025.
On May 20, 2026, Nasdaq granted an additional 180 calendar day compliance period, through November 16, 2026.
The company's common stock closed above $1.00 for at least ten consecutive business days to meet the standard.
On September 18, 2026, GT Biopharma amended its September 14 securities purchase agreement to add a new purchaser and raise the preferred stock offering to 8,611.111 shares with an aggregate purchase price of $7,750,000. The amendment also gives purchasers rights to buy additional preferred stock for an aggregate purchase price of $31,208,054, and the company increased its designated Series M preferred shares from 41,778 to 43,287, with the shares and warrants sold under Rule 506(b) and a resale registration statement to be filed.
Preferred stock offering increased to 8,611.111 shares of Series M 10% Convertible Preferred Stock, with an aggregate stated value of $8,611,111.11 and an aggregate purchase price of $7,750,000.
Purchasers may elect additional preferred stock purchases (Greenshoe Rights) with an aggregate stated value of up to $34,675,615 for an aggregate purchase price of $31,208,054.
Certificate of Increase filed September 18, 2026 raises designated Series M preferred shares from 41,778 to 43,287.
Company agreed to file a resale registration statement within 30 days after the initial closing and after each Greenshoe closing.
GT Biopharma entered into a securities purchase agreement on September 14, 2026, selling Series M 10% convertible preferred stock and warrants for an aggregate purchase price of $7,450,000, with up to $30,000,000 more available to purchasers through greenshoe rights. The preferred stock converts at an initial price of $6.10 per share and carries full ratchet price protection, so the potential dilution to existing shareholders could be substantial; the company also agreed to seek shareholder approval for issuances above 19.99% of outstanding common stock.
Aggregate purchase price of $7,450,000 for preferred stock and warrants with stated value of $8,277,778
Preferred stock and warrants have an initial price of $6.10 per share and full ratchet price protection
Purchasers may buy up to $33,333,333 of additional preferred stock for $30,000,000 under greenshoe rights
Company agreed to hold a stockholder meeting seeking approval for issuances above 19.99% of outstanding common stock
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every GT Biopharma, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →